Journal Articles The Breast Year : 2021

Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

Anne-Laure Martin
  • Function : Author
Sibille Everhard
Olivier Tredan

Abstract

We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and -1.01 [-1.98 to -0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.
Fichier principal
Vignette du fichier
S096097762100028X.pdf (595) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04769597 , version 1 (13-11-2024)

Licence

Identifiers

Cite

Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, et al.. Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast, 2021, 57, pp.43-48. ⟨10.1016/j.breast.2021.02.014⟩. ⟨hal-04769597⟩
70 View
10 Download

Altmetric

Share

More